su011248

Bladder Cancer

National Cancer Institute (NCI)Phase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 48/ 100
Competitive Position: 73/ 100

Competitive context

97 Active assets in the Bladder Cancer cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II G1 Therapeutics, Inc.	Phase 3	BBB
Carboplatin G1 Therapeutics, Inc.	Phase 3	BB
Epirubicin Merck Sharp & Dohme LLC	Phase 3	BB
Pembrolizumab Essen Biotech	Phase 3	BB
VINBLASTINE University of Southern California	Phase 3	BB

View all 50 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant

BBB

Indicative ·

75 / 100

Pancreatic Neuroendocrine TumorDormant

BB

Indicative ·

69 / 100

Renal Cell CarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.